A rare case of acute hepatitis with jaundice during treatment of human immunodeficiency virus infection with E/C/F/TAF
| Autor: | Hung-Yi Chen, Tsung-Chia Chen, Hui-Chi Chang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Elvitegravir
business.industry Cobicistat Human immunodeficiency virus (HIV) Case Report Jaundice medicine.disease_cause Emtricitabine 030226 pharmacology & pharmacy Tenofovir alafenamide Virology 03 medical and health sciences 0302 clinical medicine medicine 030212 general & internal medicine Liver function General Pharmacology Toxicology and Pharmaceutics medicine.symptom business Acute hepatitis medicine.drug |
| Zdroj: | Eur J Hosp Pharm |
| Popis: | The fixed-dose combination elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (E/C/F/TAF) is a first-line agent for the treatment of human immunodeficiency virus (HIV) infection. We report the case of a 25-year-old man with newly diagnosed HIV infection who was treated with E/C/F/TAF. The patient9s hepatitis panel results were negative. Neither illicit drug abuse nor hepatotoxic medication was reported. Significantly elevated alanine aminotransferase with jaundice was found in the fourth week during the treatment course. His liver function gradually improved after withdrawal of the medication. This is the first report to our knowledge of E/C/F/TAF-related acute hepatitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|